Rein Therapeutics (RNTX) Leases (2019 - 2022)
Rein Therapeutics (RNTX) has disclosed Leases for 4 consecutive years, with $40000.0 as the latest value for Q4 2022.
- On a quarterly basis, Leases fell 73.68% to $40000.0 in Q4 2022 year-over-year; TTM through Dec 2022 was $40000.0, a 73.68% decrease, with the full-year FY2022 number at $40000.0, down 73.68% from a year prior.
- Leases was $40000.0 for Q4 2022 at Rein Therapeutics, down from $70000.0 in the prior quarter.
- In the past five years, Leases ranged from a high of $6.5 million in Q1 2019 to a low of $40000.0 in Q4 2022.
- A 4-year average of $2.9 million and a median of $228000.0 in 2021 define the central range for Leases.
- Peak YoY movement for Leases: fell 9.93% in 2020, then crashed 96.81% in 2021.
- Rein Therapeutics' Leases stood at $6.1 million in 2019, then dropped by 8.42% to $5.6 million in 2020, then plummeted by 97.26% to $152000.0 in 2021, then tumbled by 73.68% to $40000.0 in 2022.
- Per Business Quant, the three most recent readings for RNTX's Leases are $40000.0 (Q4 2022), $70000.0 (Q3 2022), and $98000.0 (Q2 2022).